Human Parvovirus B19 Induced Apoptotic Bodies Contain Altered Self-Antigens that are Phagocytosed by Antigen Presenting Cells

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Thammasri, Kanoktip ^a   Rauhamäki, Sanna ^a   Wang, Liping ^a   Filippou, Artemis ^a   Kivovich, Violetta ^b   Marjomäki, Varpu ^a   Naides, Stanley J ^c   Gilbert, Leona ^a  

^a UNIVERSITY OF JYVÄSKYLÄ   (Finland)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOH ANTIBODY; DNA; HISTONE H4; NONSTRUCTURAL PROTEIN 1; PHOSPHATIDYLSERINE; SM ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; APOPTOSIS; APOPTOTIC BODY; ARTICLE; AUTOIMMUNITY; CANCER CELL CULTURE; CELL ACTIVITY; CELL COMPONENT; CELL DIFFERENTIATION; CELL LINE; CELL PHAGOCYTOSIS; CONTROLLED STUDY; DNA ADDUCT; ERYTHEMA INFECTIOSUM; HUMAN; HUMAN CELL; HUMAN PARVOVIRUS B19; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; LIVER CELL CARCINOMA; MACROPHAGE; MOLECULAR MECHANICS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN TRANSPORT; SF9 CELL;

ANIMALS; ANTIGEN-PRESENTING CELLS; APOPTOSIS; AUTOANTIGENS; AUTOIMMUNITY; FLOW CYTOMETRY; HEP G2 CELLS; HUMANS; IMMUNE TOLERANCE; MICROSCOPY, ELECTRON, SCANNING; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PHAGOCYTOSIS; SF9 CELLS; SPODOPTERA; VIRAL NONSTRUCTURAL PROTEINS;

ERYTHROVIRUS; PARVOVIRUS;

EID: 84878930844     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067179     Document Type: Article

References (77)

1. Clewley JP, (1984) Biochemical characterization of a human parvovirus. J Gen Virol 65(1):: 241-245. doi:10.1099/0022-1317-65-1-241.
2. Cossart YE, Field AM, Cant B, Widdows D, (1975) Parvovirus-like particles in human sera. Lancet 1: 72-73. PubMed: 46024.
3. Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR, (1986) Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 58: 921-936. PubMed: 3701931.
4. Young NS, Brown KE, (2004) Parvovirus B19. N Engl J Med 350: 586-597. doi:10.1056/NEJMra030840. PubMed: 14762186.
5. Zádori Z, Szelei J, Lacoste MC, Li Y, Gariépy S, et al. (2001) A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 1: 291-302. doi:10.1016/S1534-5807(01)00031-4. PubMed: 11702787.
6. Raab U, Beckenlehner K, Lowin T, Niller HH, Doyle S, et al. (2002) NS1 protein of parvovirus B19 interacts directly with DNA sequences of the p6 promoter and with the cellular transcription factors Sp1/Sp3. Virology 293: 86-93. doi:10.1006/viro.2001.1285. PubMed: 11853402.
7. Fu Y, Ishii KK, Munakata Y, Saitoh T, Kaku M, et al. (2002) Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol 76: 5395-5403. doi:10.1128/JVI.76.11.5395-5403.2002. PubMed: 11991968.
8. Mitchell LA, (2002) Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections? J Med Virol 67: 267-274. doi:10.1002/jmv.2217. PubMed: 11992589.
9. Young N, Harrison M, Moore J, Mortimer P, Humphries RK, (1984) Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro. J Clin Invest 74: 2024-2032. doi:10.1172/JCI111625. PubMed: 6392340.
10. Ozawa K, Kurtzman G, Young N, (1987) Productive infection by B19 parvovirus of human erythroid bone marrow cells in vitro. Blood 70: 384-391. PubMed: 3038211.
11. Srivastava A, Bruno E, Briddell R, Cooper R, Srivastava C, et al. (1990) Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. Blood 76: 1997-2004. PubMed: 2146978.
12. Munshi NC, Zhou S, Woody MJ, Morgan DA, Srivastava A, (1993) Successful replication of parvovirus B19 in the human megakaryocytic leukemia cell line MB-02. J Virol 67: 562-566. PubMed: 8416383.
13. Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugamura K, (1998) Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 72: 3018-3028. PubMed: 9525624.
14. Sol N, Le Junter J, Vassias I, Freyssinier JM, Thomas A, et al. (1999) Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J Virol 73: 8762-8770. PubMed: 10482630.
15. Poole BD, Karetnyi YV, Naides SJ, (2004) Parvovirus B19-induced apoptosis of hepatocytes. J Virol 78: 7775-7783. doi:10.1128/JVI.78.14.7775-7783.2004. PubMed: 15220451.
16. Poole BD, Zhou J, Grote A, Schiffenbauer A, Naides SJ, (2006) Apoptosis of liver-derived cells induced by parvovirus B19 nonstructural protein. J Virol 80: 4114-4121. doi:10.1128/JVI.80.8.4114-4121.2006. PubMed: 16571827.
17. Kivovich V, Gilbert L, Vuento M, Naides SJ, (2010) Parvovirus B19 genotype specific amino acid substitution in NS1 reduces the protein's cytotoxicity in culture. Int J Med Sci 7: 110-119. PubMed: 20567611.
18. Kivovich V, Gilbert L, Vuento M, Naides SJ, (2012) The putative metal coordination motif in the endonuclease domain of human Parvovirus B19 NS1 is critical for NS1 induced S phase arrest and DNA damage. Int J Biol Sci 8: 79-92. doi:10.3923/ijb.2012.79.81. PubMed: 22211107.
19. Bonvicini F, Filippone C, Manaresi E, Zerbini M, Musiani M, et al. (2008) HepG2 hepatocellular carcinoma cells are a non-permissive system for B19 virus infection. J Gen Virol 89: 3034-3038. doi:10.1099/vir.0.2008/004341-0. PubMed: 19008390.
20. Kerr JR, (1996) Parvovirus B19 infection. Eur J Clin Microbiol Infect Dis 15: 10-29. doi:10.1007/BF01586181. PubMed: 8641299.
21. Kerr S, O'Keeffe G, Kilty C, Doyle S, (1999) Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J Med Virol 57: 179-185. doi:10.1002/(SICI)1096-9071(199902)57:2. PubMed: 9892405.
22. Anderson MJ, Cohen BJ, (1987) Human Parvovirus B19 Infections in United-Kingdom 1984-86. Lancet 1: 738-739.
23. Heegaard ED, Brown KE, (2002) Human parvovirus B19. Clin Microbiol Rev 15: 485-505. doi:10.1128/CMR.15.3.485-505.2002. PubMed: 12097253.
24. Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, et al. (1985) Experimental Parvoviral Infection in Humans. J Infect Dis 152: 257-265. doi:10.1093/infdis/152.2.257. PubMed: 2993431.
25. Potter CG, Potter AC, Hatton CS, Chapel HM, Anderson MJ, et al. (1987) Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19). J Clin Invest 79: 1486-1492. doi:10.1172/JCI112978. PubMed: 3033026.
26. Lehmann HW, von Landenberg P, Modrow S, (2003) Parvovirus B19 infection and autoimmune disease. Autoimmun Rev 2: 218-223. doi:10.1016/S1568-9972(03)00014-4. PubMed: 12848949.
27. Corcoran A, Doyle S, (2004) Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 53: 459-475. doi:10.1099/jmm.0.05485-0. PubMed: 15150324.
28. Drago F, Semino M, Rampini P, Rebora A, (1999) Parvovirus B19 infection associated with acute hepatitis and a purpuric exanthem. Br J Dermatol 141: 160-161. doi:10.1046/j.1365-2133.1999.02943.x. PubMed: 10417538.
29. Yang SH, Lin LW, Fang YJ, Cheng AL, Kuo SH, (2012) Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma. Ann Hematol 91: 291-294. doi:10.1007/s00277-011-1238-8. PubMed: 21538062.
30. Pinho JR, Alves VA, Vieira AF, Moralez MO, Fonseca LE, et al. (2001) Detection of human parvovirus B19 in a patient with hepatitis. Braz J Med Biol Res 34: 1131-1138. PubMed: 11514836.
31. Arista S, De Grazia S, Di Marco V, Di Stefano R, Craxì A, (2003) Parvovirus B19 and "cryptogenic" chronic hepatitis. J Hepatol 38: 375-376. doi:10.1016/S0270-9139(03)80488-3. PubMed: 12586308.
32. Mogensen TH, Jensen JM, Hamilton-Dutoit S, Larsen CS, (2010) Chronic hepatitis caused by persistent parvovirus B19 infection. BMC Infect Dis 10: 246. doi:10.1186/1471-2334-10-246. PubMed: 20727151.
33. Nobili V, Vento S, Comparcola D, Sartorelli MR, Luciani M, et al. (2004) Autoimmune hemolytic anemia and autoimmune hepatitis associated with parvovirus B19 infection. Pediatr Infect Dis J 23: 184-185. doi:10.1097/01.inf.0000110270.38240.51. PubMed: 14872194.
34. Kordes U, Schneppenheim R, Briem-Richter A, Scherpe S, Schäfer HJ, (2011) Parvovirus B19 infection and autoimmune hepatitis in a child with sickle cell anemia. Pediatr Blood Cancer 56: 323-324. doi:10.1002/pbc.22820. PubMed: 21157899.
35. Díaz F, Collazos J, (2000) Hepatic dysfunction due to parvovirus B19 infection. J Infect Chemother 6: 63-64. doi:10.1007/s101560050052. PubMed: 11810534.
36. Dame C, Hasan C, Bode U, Eis-Hübinger AM, (2002) Acute liver disease and aplastic anemia associated with the persistence of B19 DNA in liver and bone marrow. Pediatr Pathol Mol Med 21: 25-29. doi:10.1080/pdp.21.1.25.29. PubMed: 11842976.
37. Krygier DS, Steinbrecher UP, Petric M, Erb SR, Chung SW, et al. (2009) Parvovirus B19 induced hepatic failure in an adult requiring liver transplantation. World J Gastroenterol 15: 4067-4069. doi:10.3748/wjg.15.4067. PubMed: 19705505.
38. Karetnyi YV, Beck PR, Markin RS, Langnas AN, Naides SJ, (1999) Human parvovirus B19 infection in acute fulminant liver failure. Arch Virol 144: 1713-1724. doi:10.1007/s007050050699. PubMed: 10542021.
39. Abe K, Kiuchi T, Tanaka K, Edamoto Y, Aiba N, et al. (2007) Characterization of erythrovirus B19 genomes isolated in liver tissues from patients with fulminant hepatitis and biliary atresia who underwent liver transplantation. Int J Med Sci 4: 105-109. PubMed: 17479159.
40. Sun L, Zhang JC, (2012) Acute fulminant hepatitis with bone marrow failure in an adult due to parvovirus B19 infection. Hepatology 55: 329-330. doi:10.1002/hep.24720. PubMed: 21969057.
41. Hemauer A, Beckenlehner K, Wolf H, Lang B, Modrow S, (1999) Acute parvovirus B19 infection in connection with a flare of systemic lupus erythematodes in a female patient. J Clin Virol 14: 73-77. doi:10.1016/S1386-6532(99)00038-4. PubMed: 10548133.
42. Takahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, et al. (1998) Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A 95: 8227-8232. doi:10.1073/pnas.95.14.8227. PubMed: 9653169.
43. Dorsch S, Liebisch G, Kaufmann B, von Landenberg P, Hoffmann JH, et al. (2002) The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol 76: 2014-2018. doi:10.1128/JVI.76.4.2014-2018.2002. PubMed: 11799199.
44. von Landenberg P, Lehmann HW, Knöll A, Dorsch S, Modrow S, (2003) Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 48: 1939-1947. doi:10.1002/art.11038. PubMed: 12847688.
45. von Landenberg P, Lehmann HW, Modrow S, (2007) Human parvovirus B19 infection and antiphospholipid antibodies. Autoimmun Rev 6: 278-285. doi:10.1016/j.autrev.2006.09.006. PubMed: 17412298.
46. Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, et al. (2008) Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 8: 116-120. doi:10.1016/j.autrev.2008.07.005. PubMed: 18700174.
47. Lunardi C, Tiso M, Borgato L, Nanni L, Millo R, et al. (1998) Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 28: 936-948. doi:10.1002/(SICI)1521-4141(199803)28:03. PubMed: 9541589.
48. Moffatt S, Tanaka N, Tada K, Nose M, Nakamura M, et al. (1996) A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 70: 8485-8491. PubMed: 8970971.
49. Poole BD, Kivovich V, Gilbert L, Naides SJ, (2011) Parvovirus B19 nonstructural protein-induced damage of cellular DNA and resultant apoptosis. Int J Med Sci 8: 88-96. PubMed: 21278893.
50. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH, (2010) The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLOS ONE 5: e8668. doi:10.1371/journal.pone.0008668. PubMed: 20084270.
51. Kankaanpää P, Paavolainen L, Tiitta S, Karjalainen M, Päivärinne J, et al. (2012) BioImageXD: An open, general-purpose and high-throughput image-processing platform. Nat Methods 9: 683-689. doi:10.1038/nmeth.2047. PubMed: 22743773.
52. Kerr JF, Wyllie AH, Currie AR, (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257. doi:10.1038/bjc.1972.33. PubMed: 4561027.
53. Arends MJ, Wyllie AH, (1991) Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol 32: 223-254. PubMed: 1677933.
54. Krysko DV, Denecker G, Festjens N, Gabriels S, Parthoens E, et al. (2006) Macrophages use different internalization mechanisms to clear apoptotic and necrotic cells. Cell Death Differ 13: 2011-2022. doi:10.1038/sj.cdd.4401900. PubMed: 16628234.
55. Barber GN, (2001) Host defense, viruses and apoptosis. Cell Death Differ 8: 113-126. doi:10.1038/sj.cdd.4400823. PubMed: 11313713.
56. Radic M, Marion T, Monestier M, (2004) Nucleosomes are exposed at the cell surface in apoptosis. J Immunol 172: 6692-6700. PubMed: 15153485.
57. Casciola-Rosen LA, Anhalt G, Rosen A, (1994) Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179: 1317-1330. doi:10.1084/jem.179.4.1317. PubMed: 7511686.
58. Cline AM, Radic MZ, (2004) Apoptosis, subcellular particles, and autoimmunity. Clin Immunol 112: 175-182. doi:10.1016/j.clim.2004.02.017. PubMed: 15240161.
59. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, et al. (1992) Exposure of Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages. J Immunol 148: 2207-2216. PubMed: 1545126.
60. Ozawa K, Ayub J, Kajigaya S, Shimada T, Young N, (1988) The Gene Encoding the Nonstructural Protein of B19 (Human) Parvovirus May Be Lethal in Transfected Cells. J Virol 62: 2884-2889. PubMed: 2969055.
61. Meyer O, (2003) Parvovirus B19 and autoimmune diseases. Joint Bone Spine 70: 6-11. doi:10.1016/S1297-319X(02)00004-0. PubMed: 12639611.
62. Murphy PM, (2001) Viral exploitation and subversion of the immune system through chemokine mimicry. Nat Immunol 2: 116-122. doi:10.1038/84214. PubMed: 11175803.
63. Alcami A, (2003) Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 3: 36-50. doi:10.1038/nri980. PubMed: 12511874.
64. Bruggeman LA, (2007) Viral subversion mechanisms in chronic kidney disease pathogenesis. Clin J Am Soc Nephrol 2 Suppl 1: S13-S19. doi:10.2215/CJN.04311206. PubMed: 17699505.
65. Baens M, Noels H, Broeckx V, Hagens S, Fevery S, et al. (2006) The Dark Side of EGFP: Defective Polyubiquitination. PLOS ONE 1: e54. doi:10.1371/journal.pone.0000054. PubMed: 17183684.
66. Liu HS, Jan MS, Chou CK, Chen PH, Ke NJ, (1999) Is green fluorescent protein toxic to the living cells? Biochem Biophys Res Commun 260: 712-717. doi:10.1006/bbrc.1999.0954. PubMed: 10403831.
67. Panoutsakopoulou V, Sanchirico ME, Huster KM, Jansson M, Granucci F, et al. (2001) Analysis of the relationship between viral infection and autoimmune disease. Immunity 15: 137-147. doi:10.1016/S1074-7613(01)00172-8. PubMed: 11485745.
68. Wagner B, Vierhapper H, Hofmann H, (1996) Prevalence of hepatitis C virus infection in Hashimoto's thyroiditis. BMJ 312: 640-641. doi:10.1136/bmj.312.7031.640b. PubMed: 8595364.
69. Vento S, Guella L, Mirandola F, Cainelli F, Di Perri G, et al. (1995) Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 346: 608-609. doi:10.1016/S0140-6736(95)91438-2. PubMed: 7651006.
70. Lawson CM, O'Donoghue HL, Reed WD, (1992) Mouse cytomegalovirus infection induces antibodies which cross-react with virus and cardiac myosin: A model for the study of molecular mimicry in the pathogenesis of viral myocarditis. Immunology 75: 513-519. PubMed: 1315309.
71. von Herrath MG, Oldstone MB, (1996) Virus-induced autoimmune disease. Curr Opin Immunol 8: 878-885. doi:10.1016/S0952-7915(96)80019-7. PubMed: 8994870.
72. Wraith DC, Goldman M, Lambert PH, (2003) Vaccination and autoimmune disease: what is the evidence? Lancet 362: 1659-1666. doi:10.1016/S0140-6736(03)14802-7. PubMed: 14630450.
73. Frisoni L, McPhie L, Colonna L, Sriram U, Monestier M, et al. (2005) Nuclear autoantigen translocation and autoantibody opsonization lead to increased dendritic cell phagocytosis and presentation of nuclear antigens: a novel pathogenic pathway for autoimmunity? J Immunol 175: 2692-2701. PubMed: 16081846.
74. Schiller M, Bekeredjian-Ding I, Heyder P, Blank N, Ho AD, et al. (2008) Autoantigens are translocated into small apoptotic bodies during early stages of apoptosis. Cell Death Differ 15: 183-191. doi:10.1038/sj.cdd.4402239. PubMed: 17932498.
75. Cline AM, Radic MZ, (2004) Murine lupus autoantibodies identify distinct subsets of apoptotic bodies. Autoimmunity 37: 85-93. doi:10.1080/0891693042000196219. PubMed: 15293878.
76. Cocca BA, Cline AM, Radic MZ, (2002) Blebs and apoptotic bodies are B cell autoantigens. J Immunol 169: 159-166. PubMed: 12077241.
77. Murphy K, Travers P, Walport M, (2008) Janeway's immunobiology. New York Garlan. Science Publishing House.